Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
pharmaphorum30m
From PDURS to D2C, Frontiers Health speaks to cutting edge healthcare news
One of the biggest market access stories this year has been the launch of Lilly Direct (and, subsequently, PfizerForAll .) ...
Everyone’s on Ozempic. So why will no one talk about it?
That Ozempic (or Wegovy, the name by which the weight-loss version of the drug semaglutide is marketed) should have proliferated in an industry that has always venerated thinness will hardly come as a ...
Swissinfo47m
European Stocks Test New Highs on Rate-Cut Bets, China Stimulus
By contrast, healthcare stocks, typically seen as safety plays, were the day’s worst performers. Novo Nordisk A/S shares ...
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Shares of Cassava Sciences, Inc. SAVA fell sharply in today's pre-market trading after the SEC charged the company, two ...
Mazda, Fiat Chrysler Recall Vehicles Over Bosch Airbag Controls
Mazda and Fiat Chrysler Automobiles both issued recalls over a software error in airbag-control modules manufactured by Robert Bosch GmbH's North American subsidiary. The National Highway Traffic ...